
Nadia Ewing MD
Pediatric Coagulation Disorder Hematology
Clinical Professor of Pediatrics. Director, Hemopphilia Comprehensive Treatment Center: Director, Sickle Cell Disease Treatment Center, Director Hematology Consultation, City of Hope
Join to View Full Profile
439 Madeline DrPasadena, CA 91105
Phone+1 626-354-2736
Dr. Ewing is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Nadia Ewing is a specialist in Pediatric Hematology & Oncology with a subspecialty in Pediatric Coagulation Disorder Hematology. She completed her fellowship at LACUSC Medical Center and has held prominent roles including Director positions at the City of Hope Comprehensive Cancer Center and Huntington Hospital Pediatric Hematology/Oncology Center. She has considerable experience in treating conditions such as sickle cell disease, beta thalassemia, and hemophilia. Dr. Ewing has published multiple studies on hemophilia and related subjects and has contributed to several clinical trials focusing on immune tolerance induction in hemophilia patients. Her work has been recognized with honors such as Top Doctors from Pasadena Magazine and Best Doctors in America.
Education & Training
Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 1978 - 1980
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Pediatrics, 1977 - 1978
University of Southern California/LACUSC Medical CenterInternship, Transitional Year, 1971 - 1972
Keck School of Medicine of the University of Southern CaliforniaClass of 1971
University of California, Los AngelesB.A., Zoology, 1967
Certifications & Licensure
CA State Medical License 1972 - 2020
AL State Medical License 1972 - 1973
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Top Doctors Pasadena Magazine, 2010
- Best Doctors in America 2007
- Fellow (FAAP) American Academy of Pediatrics
Clinical Trials
- Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) Start of enrollment: 2009 Nov 03
- Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive Start of enrollment: 2009 Sep 25
- Survey of Inhibitors in Plasma-Product Exposed Toddlers Start of enrollment: 2010 Jan 01
Publications & Presentations
PubMed
- 8 citationsHemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators.Ahmad Faisal Karim, Anthony R. Soltis, Gauthaman Sukumar, Christoph Königs, Nadia P. Ewing
Frontiers in Immunology. 2020-06-12 - 3 citationsTransfusion of multiple units of Js(b+) red blood cells in the presence of anti-Jsb in a patient with sickle beta-thalassemia disease and a review of the literature.Shan Yuan, Nadia P. Ewing, Debra Bailey, Marissa Salvador, Shirong Wang
Immunohematology. 2020-04-01 - 369 citationsA Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia AFlora Peyvandi, Pier Mannuccio Mannucci, Isabella Garagiola, Amal El-Beshlawy, Mohsen Saleh Elalfy
The New England Journal of Medicine. 2016-05-25
Journal Articles
- Consequences of Switching From Prophylactic Treatment to On Demand Treatment in Late Teens and Early Adults With Severe Hemophilia A: The TEEN/TWEN StudyManco-Johnson, M, Sanders, J, Ewing, N, Rodriguez, N, Tarantino, Humphries, T and the TEEN/TWEN Study Group, Haemophilia, 1/1/2013
- Identifying Nonresponsive Bleeding Episodes in Patients with Hemophilia and Inhibitors: A Consensus DefinitionBerntorp, E, Collins, P., D’Oiron, R., Ewing, N., Gringeri, A, Negrier, C., Young, G, Haemophilia, 1/1/2010
- Experience with a Third Generation Recombinant Factor VIII Concentrate (Advate) for Immune Tolerance induction in Patients with Hemophilia AValentino, L.,Recht,M.,DiPaola, J.,Shapiro, A.,Pipe, S., Ewing, N., Urgo, J.,Bullock, T.,Simmons, M., and Deguzman, C., Haemophilia, 1/1/2009
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include up-Regulated Innate Immune ModulatorsNadia P Ewing, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Current Evidence For Prophylaxis in Pediatric Patients With Inhibitors.Ewing, N.P., Latin American Hemophilia Study Update, Cartagena, Colombia, 1/7/2014
- Transition from Pediatric to Adult PanelEwing, N.P., Region IX Hemophilia Treatment Center Annual Meeting, Santa Monica, CA, 1/29/2012
- Join now to see all
Lectures
- The OB/GYN’s Role in von Willebrand Disease (VWD) Detection.Pasadena, CA - 1/30/2009
- Immune Tolerance Induction in Hemophilia A and B.City of Hope, Duarte, CA - 1/23/2009
- Prophylaxis in Hemophilia Patients with Inhibitors.Montebello, Canada - 1/6/2009
- Join now to see all
Other
- Strategies for Life. Prophylaxis Therapy for Hemophilia Patients with Inhibitors. Series I, II, III.Ewing, N.P., Stine, K.C., Series I, II, III. CME Monographs
http://www.myinhibitorcme.com
1/1/2007 - AIDS – An Update (Television Program)Ewing, N.P., Antenna Sud, Bari, Italy
1/22/1998 - AIDS and Hemophilia.Ewing, N.P., Antenna Sud, Bari, Italy
1/25/1985
Professional Memberships
- Fellow
Other Languages
- Spanish, French, Italian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









